article thumbnail

STAT+: Health plan formularies lowered barriers to fair access to some drugs, analysis finds

STAT

generally provide “fair access” to 11 treatments for several serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis has found. Most of the formularies run by some of the largest health plans in the U.S. Continue to STAT+ to read the full story…

article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1

Diabetes 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How the FDA’s new nutrition labels could prod the food industry to get healthier 

STAT

A new government proposal to display nutritional labels on the front of food packaging is aimed at helping Americans make more informed choices about what they eat. An eventual side effect, research and expert commentary suggests, could be nudging the food industry to make healthier food, too.

Labelling 324
article thumbnail

Can screening for food insecurity make a difference for patients? The jury is out

STAT

For someone diagnosed with diabetes, for example, access to nutritious food can be just as important as insulin. But even as new federal incentives require health systems to collect information that would help them identify if that new diabetes patient lives in a food desert, it’s not always clear what to do with that information.

Diabetes 308
article thumbnail

GLP-1 drugs not linked to suicidal thoughts in FDA’s early review

STAT

A preliminary evaluation by the Food and Drug Administration did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.

Diabetes 348
article thumbnail

STAT+: FDA cracks down on websites that claim to sell chemicals in obesity drugs Wegovy, Zepbound

STAT

The Food and Drug Administration is cracking down on websites that claim to sell the underlying chemicals of popular diabetes and obesity drugs like Ozempic, Wegovy, and Zepbound, saying that the websites are selling unapproved and misbranded drug products. DBA Helix Chemical Supply and US Chem Labs.

Diabetes 342
article thumbnail

Opinion: The influential adverse childhood experiences questionnaire should ask about gun violence

STAT

This information guides the implementation of preventive measures like lifestyle counseling to reduce the risk of ACE-related chronic conditions like depression, obesity, asthma, diabetes, and cancer. It offers physicians a screening tool to evaluate patients, gaining valuable insights into their physical and mental well-being.

Diabetes 313